Journal article · 2025 · Open access

ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY

M. Pontes Ferreira, A. Cunha, Catarina Dantas Soares, S. Almeida, Flavia Alice T. M. Guimarães, José Tavares‐Costa

Annals of the Rheumatic Diseases, 84, 2034–2035 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.1618

Open full textCite this paper

In brief

“ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY” is a 2025 journal article by M. Pontes Ferreira and 5 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
0
Authors
6

Abstract

Background: Advances in rheumatoid arthritis (RA) treatment, particularly with the use of biologic and targeted synthetic disease-modifying antirheumatic drugs (b-/ts-DMARDs), have improved patient outcomes over the last decades. Tumour necrosis factor inhibitors (TNFi) remain central to RA therapy, while newer agents like Janus kinase inhibitors (JAKi) and IL-6 inhibitors (tocilizumab, TCZ) offer alternative mechanisms of action [1]. With no doubt, these therapies are efficacious, however, some trials raised concerns over increased rates of malignancies with the use of ts-DMARDs [2–4]. Objectives: To assess and compare the incidence of malignancies in RA patients treated with JAKi, TCZ and TNFi. Methods: A retrospective single-centre observational study was conducted including patients with RA, fulfilling the 2010 ACR/EULAR classification criteria, that received TNFi, TCZ or JAKi from January 2000 to October 2024. Electronic medical records were reviewed for sociodemographic data, comorbidities, disease characteristics and activity, concomitant treatment, number and type of malignancies. Treatment groups were compared using Student's T-test/ Mann-Whitney's U test or the chi-squared test, as appropriate. The incidence of malignancies was estimated and compared using Kaplan-Meier survival analysis and Log-Rank test. Statistical significance was defined as p<0.05 for all analyses, and analyses were conducted using SPSS Statistics v.21. Results: This study included 198 RA patients treated with TNFi, JAKi or TCZ, of whom 165 had malignancy-related data available. Of these, 114 were treated with TNFi and 51 with JAKi/TCZ (Table 1). The cohort consisted of 72.1% women, with a mean age at diagnosis of 45 years and a median disease duration of 5.6 years at the start of b-/ts-DMARDs. Malignancy occurred in 12 patients (7.3%) after b-/ts-DMARD therapy initiation: 8 cases (7.0%) in the TNFi group and 4 cases (7.8%) in the JAKi/TCZ group. These malignancies included 4 breast cancers, 3 genitourinary cancers (1 renal cancer and 2 prostatic cancers), 2 lung cancers, 2 head and neck cancers, and 1 pancreatic cancer. Sixty-six of these patients (n=8) were female with mean age of 60±13 years-old and 91.7% (n=11) had cardiovascular risk factors at the time of the cancer diagnosis, including smoking history (54.4%). The mean survival time was 242.2 months (95% CI: 215.9–268.6) and 149.4 months (95% CI: 130.4–168.5) for TNFi and JAKi/TCZ groups, respectively. The Kaplan-Meier analysis showed no statistically significant difference in malignancy-free survival between groups (Figure 1). The survival rates at the end of the study were >90% in both groups, indicating low overall event rates. The incidence of malignancies was 12.8 per 1,000 person-years in the TNFi group and 19.16 in the JAKi/TCZ group, respectively. Two patients died…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ferreira, M. P., Cunha, A., Soares, C. D., Almeida, S., Guimarães, F. A. T. M., & Tavares‐Costa, J. (2025). ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY. Annals of the Rheumatic Diseases, 84, 2034–2035. https://doi.org/10.1016/j.ard.2025.06.1618

MLA 9

Ferreira, M. Pontes, et al. “ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 2034–2035. https://doi.org/10.1016/j.ard.2025.06.1618.

Chicago

Ferreira, M. Pontes, A. Cunha, Catarina Dantas Soares, S. Almeida, Flavia Alice T. M. Guimarães, and José Tavares‐Costa. 2025. “ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY.” Annals of the Rheumatic Diseases 84: 2034–2035. https://doi.org/10.1016/j.ard.2025.06.1618.

Harvard

Ferreira, M. P. et al. (2025) ‘ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY’, Annals of the Rheumatic Diseases, 84, pp. 2034–2035. doi:10.1016/j.ard.2025.06.1618.

IEEE

M. P. Ferreira, A. Cunha, C. D. Soares, S. Almeida, F. A. T. M. Guimarães, and J. Tavares‐Costa, “ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY,” Annals of the Rheumatic Diseases, vol. 84, pp. 2034–2035, 2025, doi: 10.1016/j.ard.2025.06.1618.

BibTeX

@article{ferreira2025cancer,
  title     = {{ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY}},
  author    = {Ferreira, M. Pontes and Cunha, A. and Soares, Catarina Dantas and Almeida, S. and Guimarães, Flavia Alice T. M. and Tavares‐Costa, José},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2025},
  volume    = {84},
  pages     = {2034--2035},
  doi       = {10.1016/j.ard.2025.06.1618},
  url       = {https://doi.org/10.1016/j.ard.2025.06.1618}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • cancer incidence
  • cancer risk
  • JAK inhibitors
  • tocilizumab
  • IL-6 inhibitors
  • tumor necrosis factor inhibitors
  • biologic DMARDs

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Ferreira, M. P., Cunha, A., Soares, C. D., Almeida, S., Guimarães, F. A. T. M., & Tavares‐Costa, J. (2025). ABS0883 CANCER INCIDENCE ON JAK INHIBITORS AND TOCILIZUMAB VS. TNF INHIBITORS USE IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE SINGLE-CENTRE STUDY. Annals of the Rheumatic Diseases, 84, 2034–2035. https://doi.org/10.1016/j.ard.2025.06.1618

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.

Who wrote this paper?

M. Pontes Ferreira, A. Cunha, Catarina Dantas Soares, S. Almeida, Flavia Alice T. M. Guimarães, José Tavares‐Costa.

What is the DOI of this paper?

10.1016/j.ard.2025.06.1618, permanently at https://doi.org/10.1016/j.ard.2025.06.1618. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.